ReviewCurrent urology reports2017
Update on Renal Mass Biopsy.
Review in Current urology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of raman spectroscopy in the diagnosis of kidney cancer: A systematic review and meta-analysis.Medicine · 2020Pooled it
- UNIK (Urologic Non-Neoplastic Investigation of Kidneys): a machine learning approach to decode benign lesion.World journal of urology · 2025Article
- [Application of Raman-based technologies in the detection of urological tumors].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative.European urology open science · 2021Article
- Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.Journal of proteome research · 2021Article
- Surveillance for low-risk kidney cancer: a narrative review of contemporary worldwide practices.Translational andrology and urology · 2021Review
- Predicting the ISUP grade of clear cell renal cell carcinoma with multiparametric MR and multiphase CT radiomics.European radiology · 2020Article
- Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management.World journal of urology · 2019Review
- Accuracy and safety of ultrasound-guided percutaneous needle core biopsy of renal masses: A single center experience in China.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal masses are diagnosed with an increasing frequency. However, a significant proportion of these masses are benign, and the majority of malignant tumors are biologically indolent. Furthermore, renal tumors are often harbored by the elderly and comorbid patients. As such, matching of renal tumor biology to appropriate treatment intensity is an urgent clinical need. Renal mass biopsy is currently a very useful clinical tool that can assist with critical clinical decision-making in patients with renal mass. Yet, renal mass biopsy is associated with limitations and, as such, may not be appropriate for all patients.
Indexed as
Identifiers
28251484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.